Women are more likely to survive cancer than men but face a higher risk of serious and adverse side effects from treatment, according to a landmark international study from Adelaide University.

Shouting at your workers causes more insidious damage than some bruised egos.

In this study, researchers aimed to determine whether the addition of durvalumab to gemcitabine plus cisplatin increases time toxicity.

Severe CRS appeared numerically less frequent than in ZUMA-3, suggesting potential differences in patient selection, supportive care, grading, or real-world mitigation strategies. Tocilizumab and ...

PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study This cross-sectional study included 75 ...

New research from a University of Cincinnati Cancer Center study found external beam radiation therapy (EBRT) is safe to ...

The findings emphasize a need for policies that may offset the impact of direct and indirect costs for patients with breast cancer. Breast cancer treatment is associated with substantial financial ...

Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA) Patients were randomly assigned to ...

A new study found that in a marine environment, microplastics absorb and concentrate toxic organic substances and thus increase their toxicity by a factor of 10, which may lead to a severe impact on ...